Dr. Barbour completed medical school at the University of Colorado in 1984 and accepted an internal medicine residency at the same institution from 1984-1987. She joined the faculty in the division of General Internal Medicine in 1987 and received a co-appointment in the Department of Obstetrics and Gynecology as an assistant professor in 1991 due to her role as medicine consultant for High Risk Obstetrics and Co-Director of their High Risk OB and Diabetes in Pregnancy Clinics. In 1992, she completed a fellowship in the Department of Preventive Medicine and Biometrics and received a Masters of Science in Public Health. Dr. Barbour was promoted to associate professor in Medicine and Obstetrics and Gynecology in 1996 with joint positions in the General Internal Medicine division and Maternal-Fetal-Medicine division , and has been listed in Best Doctors in America every year since that time. Due to her increasing interest in the area of endocrinology of pregnancy and translational research, she left the General Internal Medicine division in July of 1999 and pursued a fellowship at UCHSC in the division of Endocrinology, Metabolism, and Diabetes. She completed the three year fellowship in June of 2002, became board certified in Endocrinology, and was promoted in 2008 to full professor in the divisions of Endocrinology, Metabolism, and Diabetes and Maternal-Fetal-Medicine. She was awarded a K-23 grant to study insulin signaling in women with gestational diabetes during pregnancy and in the postpartum period. Recently, she was awarded an NIH R-56 grant to better understand what excess nutrients in mothers who are obese or have had gestational diabetes might program obesity in the newborn. She is p ast President of the North American Society of Obstetric Medicine, has served on the Pregnancy Council for the American Diabetes Association, and chaired the Colorado Clinical Guidelines Collaborative for Management of Gestational Diabetes for the state health department. She has published over 50 manuscripts, book chapters, and guidelines in the area of Obstetric Medicine and is a co-editor of the textbook “Medical Care of the Pregnant Patient”, for which the 2 nd edition was published by the ACP in 2008, and a co-author of the Endocrine Society Guidelines on Thyroid Dysfunction in Pregnancy and Postpartum , published in 2007.

Selected Publications

• Barbour, LA, McCurdy CE, Knotts TA, Shao J, Kirwan J Catalano P, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 2007; 30:S1-8. PUBMED
  
  
• Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, Mandel SJ, Stagnaro-Green A. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007;92(8):S1-47. PUBMED
  
  
• Kahn BF, Davies JK, Lynch AM, Reynolds RM, Barbour LA. Predictors of glyburide failure in the treatment of gestational diabetes. Obstet Gynecol 2006:107(6):1303-9. PUBMED
  
  
• Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, Vo Y, McCurdy CE, Yakar S, Leroith D, Kahn CR, Cantley LC, Friedman JE, Draznin B. . Increased p85 a is a potent negative regulator of skeletal muscle insulin signaling and induces in-vivo insulin resistance associated with growth hormone excess. JBC 2005;280:45:37489-94. PUBMED
  
  
• Barbour LA, Oja J, Schultz L. A prospective trial demonstrating LMWH (Dalteparin) requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004;191:1024-9. PUBMED
  
  
• Barbour LA, Shao J, Qiao J. Human placental growth hormone increases expression of the p85a regulatory unit of PI 3-kinase and triggers severe insulin resistance in muscle. Endocrinology 2004;145:1144-50. PUBMED